secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2026-02-06T23:59:59+00:00
Accession:  0001640334-26-000230
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria Bioscience receives Nasdaq bid price deficiency notice; 180 days to cure
--------------------------------------------------------------------------------

- Received Nasdaq deficiency notice on Feb 4, 2026 for failing to meet $1.00 min bid price (Rule 5550(a)(2)).
- Compliance period runs 180 calendar days, until August 3, 2026, to regain compliance.
- To cure, closing bid price must be ≥$1.00 for at least 10 consecutive business days during period.
- If not cured, company may seek second 180-day period if it meets other initial listing standards.
- Failure to regain compliance could lead to delisting; company is evaluating options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033426000230/0001640334-26-000230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033426000230/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-26-000230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer